Nitrogen Containing Compound Doai Patents (Class 514/740)
-
Publication number: 20120213861Abstract: Rodenticide compositions that include 2-chloropentafluoropropene, and methods of using such rodenticide compositions, are provided. The rodenticide compositions can be used as fumigants in space fumigation applications. In some examples, the rodenticide compositions can be used as drop-in replacements for methyl bromide in existing rodenticide compositions and methods of exterminating rodents using methyl bromide.Type: ApplicationFiled: February 22, 2011Publication date: August 23, 2012Applicant: HONEYWELL INTERNATIONAL INC.Inventors: Andrew Joseph Poss, Rajiv Ratna Singh, David Nalewajek, Cheryl Cantlon
-
Patent number: 8246988Abstract: In one aspect, the present invention features a tablet including a first drug layer, a second drug layer, and a third drug layer, wherein (i) the first drug layer includes naproxen; (ii) a second drug layer including pseudoephedrine; and (iii) the third drug layer includes cetirizine; wherein the first drug layer is in contact with the second drug layer, the third drug layer is in contact with the second drug layer, and the first drug layer is not in contact with the third drug layer, and wherein the second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours.Type: GrantFiled: January 4, 2010Date of Patent: August 21, 2012Assignee: McNeil-PPC, Inc.Inventors: Satish Kamath, Indukumar G. Shah, Michael Nichols, Dinesh Patel
-
Patent number: 8227517Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.Type: GrantFiled: February 11, 2009Date of Patent: July 24, 2012Assignee: Tosk, IncorporatedInventors: William A. Garland, Brian D. Frenzel
-
Publication number: 20120172340Abstract: Methods for identifying selective activators of SIRT5 and/or SIRT1 and methods for using these selective activators in the modulation of SIRT5 and/or SIRT1 are provided.Type: ApplicationFiled: October 7, 2010Publication date: July 5, 2012Applicant: BIOMOL International L.P.Inventors: Konrad T. Howitz, Robert E. Zipkin
-
Patent number: 8211945Abstract: Methods for stabilizing ?-galactosidase, stabilizing ?-glucocerebrosidase, treating a glycolipid metabolic disorder caused by mutation of ?-galactosidase gene, treating a glycolipid metabolic disorder caused by mutation of ?-glucocerebrosidase gene, regenerating the activity of ?-galactosidase, regenerating the activity of ?-glucosidase, treating GM1 gangliosidosis, Morquio-B or Krabbe's disease, and treating Gaucher's disease, include administering a carba-sugar amine derivative represented by the following formula (1) or (2):Type: GrantFiled: June 24, 2009Date of Patent: July 3, 2012Assignee: Seikagaku CorporationInventors: Seiichiro Ogawa, Yoshiyuki Suzuki, Eiji Nanba, Junichiro Matsuda, Kousaku Ohno
-
Publication number: 20120149678Abstract: The invention provides organonitro compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat non-Hodgkin's lymphoma and certain leukemias in a patient. The compounds, compositions, kits, and methods are contemplated to provide a therapeutic benefit in treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, and acute lymphoblastic leukemia. Exemplary organonitro compounds described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.Type: ApplicationFiled: December 9, 2011Publication date: June 14, 2012Inventors: Bryan T. Oronsky, Susan Knox, Jan Scicinski, Shoucheng Ning
-
Publication number: 20120121723Abstract: An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: Sterilex Technologies, LLCInventors: Pradip Mookerjee, Shira Kramer, Alexander Josowitz, April Zambelli-Weiner
-
Patent number: 8178584Abstract: The present invention relates to a water-in-oil emulsified composition containing a sphingosine represented by the following formula (1): (R1 represents a hydrocarbon group optionally having a substituent; Y represents methylene, methine or O; X1, X2 and X3 each represent H, OH or acetoxy group; X4 represents H, acetyl group or the like; R2, R3 each represents H, OH or the like; R represents H, amidino group or the like; and a stands for 2 or 3), (B) a C6-30 fatty acid, and (C) an oil component. This water-in-oil emulsified composition has excellent stability and provides a good feeling to skin upon use.Type: GrantFiled: June 9, 2004Date of Patent: May 15, 2012Assignee: Kao CorporationInventors: Koji Okubo, Yumiko Yamamoto
-
Patent number: 8163799Abstract: Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.Type: GrantFiled: December 10, 2007Date of Patent: April 24, 2012Assignee: Genzyme CorporationInventors: Pradeep K. Dhal, Stephen Randall Holmes-Farley, Chad C. Huval
-
Patent number: 8158117Abstract: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrochloride, hydrobromide, hydroacetate or hydroanionic form.Type: GrantFiled: September 13, 2006Date of Patent: April 17, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Katie Beth Williams, Katarzyna Barcyka
-
Patent number: 8138228Abstract: A liquid kelp formulation includes an enzyme inactivating component and a preservative to extend the shelf life of the formulation in terms of growth hormones. The formulation can also include a fertilizing additive, and a surfactant. A system is also provided whereby the kelp is maintained in solid form, and dissolved in water just prior to use. The solid form kelp and/or water can include additives, or additives in separate form, if used, can be added to either the kelp or the kelp solution.Type: GrantFiled: October 8, 2008Date of Patent: March 20, 2012Assignee: Accelegrow Technologies, Inc.Inventor: Louis B. Johnson
-
Patent number: 8133919Abstract: A growth hormone formulation includes an enzyme inactivating component and a preservative. The formulation can be incorporated into a dry fertilizer for application using the fertilizer itself or a component of the fertilizer such as one or more of the fillers commonly used in fertilizers.Type: GrantFiled: October 14, 2008Date of Patent: March 13, 2012Assignee: Accelegrow Technologies, Inc.Inventors: Louis B. Johnson, Jeffery L. Peel
-
Patent number: 8133920Abstract: A growth hormone formulation includes an enzyme inactivating component and a preservative. The formulation can also include a fertilizing additive, and a surfactant. The growth hormone can be a natural one such as that found in kelp or a synthetic one or a combination of both.Type: GrantFiled: November 25, 2008Date of Patent: March 13, 2012Assignee: Accelegrow Technologies, Inc.Inventors: Louis B Johnson, Jeffery L Peel
-
Patent number: 8106080Abstract: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R1 is H, halo, C1-6 alkoxy or C1-6 alkyl; R2 is H, NO2 or C(O)NH2; R3 is H, NO2 or C(O)NH2; and at least one of R2 and R3 is NO2; or a pharmaceutically acceptable salt of the compound.Type: GrantFiled: June 8, 2006Date of Patent: January 31, 2012Inventors: Gu-Qi Wang, Frank J Burczynski, Judith E Anderson
-
Patent number: 8097274Abstract: Provided herein are skin substitutes suitable for use in a living subject for purpose of repairing damaged tissues, methods of producing the skin substitutes and their uses. A biocomposite membrane comprising poly(?-caprolactone) (PCL) and at least one material selected from collagen and gelatin is provided. In one embodiment, the biocomposite is a 2-component membrane of PCL and gelatin. In another embodiment, the biocomposite is a 3-component membrane of PCL, collagen and gelatin. The bio-composite membrane may be used directly in vivo as a wound dressing, or as a support for cell growth on each side of the membrane to produce an in vitro cultivated artificial skin for future in vivo and/or in vitro applications.Type: GrantFiled: October 27, 2006Date of Patent: January 17, 2012Assignee: National Defense Medical CenterInventors: Allan Gerald Arthur Coombes, Eric Frank Adams, Niann-Tzyy Dai, Tsung-Hsun Liu, Ming-Kung Yeh
-
Patent number: 8093258Abstract: The present invention relates to methods and compositions for the treatment and/or prevention of neuropathological and/or neurodegenerative diseases. In particular, the invention delivers novel uses of inhibitors of Urokinase-type Plasminogen activator in the treatment of amyotrophic lateral sclerosis.Type: GrantFiled: June 22, 2006Date of Patent: January 10, 2012Assignee: Wilex AGInventors: Stefan Lorenzl, Wolfgang Schmalix
-
Patent number: 8092661Abstract: The invention relates to novel electropolymerisable monomers which are to be polymerised in an aqueous solution and comprise: an electropolymerisable pattern selected from acetylene, pyrrols, thiophenes, indols, anilines, azines, p-phenylene vinylenes, p-phenylenes, pyrenes, furanes, selenophenes, pyrridazines, carbazoles, acrylates, methacrylates and the derivatives thereof, and a metalloporphyrine which is substituted by at least two ionised or ionizable entities in an aqueous solution. The invention also relates to a method for the polymerization of such monomers, to the electroactive probe that can be obtained by the polymerization of such monomers, and to a method for detecting a target ligand in a biological sample using one such electroactive probe.Type: GrantFiled: November 2, 2006Date of Patent: January 10, 2012Assignees: Biomerieux, Centre National de la Recherche Scientifique (CNRS), Universite Paris SUDInventors: Frédéric Canonne, Hafsa Korri-Youssoufi, Jean-Pierre Mahy, Bernard Mandrand, Martine Perree-Fauvet
-
Patent number: 8071630Abstract: A method of treating an effect of a chemical agent, which agent is characterized by one or more chiral centres, by administering a dilution or an ultra-high dilution or potentised preparation of a stereoisomer of said chemical agent.Type: GrantFiled: February 28, 2003Date of Patent: December 6, 2011Inventor: Reinhard Michael Kuzeff
-
Patent number: 8048996Abstract: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering various biologically active molecules.Type: GrantFiled: August 20, 2010Date of Patent: November 1, 2011Assignees: Postech Foundation, Postech Academy-Industry FoundationInventors: Sung-Kee Chung, Kaustabh Kumar Maiti, Woo Sirl Lee, Ock-Youm Jeon, Seok-Ho Lee
-
Patent number: 8025651Abstract: A urinary anti-backflow device is provided which prevents urine from flowing back into the patient's bladder from a urine collection bag. The device comprises a flow tube having an upstream section connectable to an external urinary device secured to a patient and a downstream section connectable to a urine collection bag, a rod within the flow tube, and a stopper which moves along the rod between the downstream and upstream ends of the flow tube. When the upstream section of the flow tube is elevated relative to the downstream section, urine from the patient is free to flow through the flow tube. When the downstream section of the flow tube is elevated relative to the upstream section, urine forces the stopper against the upstream section to prevent backflow.Type: GrantFiled: March 17, 2009Date of Patent: September 27, 2011Inventor: Carl Hart
-
Patent number: 8013018Abstract: Provided is a compound that is an NMDA receptor antagonist having a broader safety margin, and is useful as an agent for treating or preventing Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, or pain. A novel compound or a salt thereof, which is characterized in that it has an amino group and R1 (lower alkyl, cycloalkyl, -lower alkylene-aryl, aryl which may be substituted, and the like) on carbon atoms of indane, cyclopenta[b]thiophene, cyclopenta[b]furan, cyclopenta[b]pyridine, or cyclopenta[c]pyridine ring, or 2,3 -dihydro-1-benzofuran, 2,3-dihydro-1-benzothiophene, indoline ring, or the like, and has R2 and R3 (the same or different, each lower alkyl or aryl) on carbon atoms beside them, and an NMDA receptor antagonist comprising the same as an active component.Type: GrantFiled: July 17, 2007Date of Patent: September 6, 2011Assignee: Astellas Pharma Inc.Inventors: Satoshi Hayashibe, Shingo Yamasaki, Kazushi Watanabe, Nobuyuki Shiraishi, Daisuke Suzuki, Hiroaki Hoshii, Junya Ohmori, Takatoshi Kanayama
-
Patent number: 8008345Abstract: There is provided a method for preventing, alleviating symptoms or treating a skin condition comprising topically administering to the skin of a subject a cosmetic or pharmaceutical topical formulation comprising an effective skin-penetrating amount of one or more phosphate derivatives of one or more electron transfer agents.Type: GrantFiled: July 26, 2002Date of Patent: August 30, 2011Assignee: Vital Health Sciences Pty. Ltd.Inventors: Simon Michael West, Robert J. Verdicchio, David Kannar, Otto H. Mills, Jr.
-
Patent number: 8003086Abstract: Disclosed herein is a cosmetic and/or pharmaceutical composition comprising, in a physiologically acceptable medium, a fatty phase and at least one compound chosen from compounds of formula (I), salts thereof, and isomers thereof, used to texture the fatty phase. Also disclosed herein is a method for texturing a cosmetic and/or pharmaceutical composition comprising adding to the composition at least one compound of formula (I). Further disclosed herein is a method for the cosmetic treatment of keratin materials comprising applying to the materials at least one composition of the present disclosure.Type: GrantFiled: May 9, 2007Date of Patent: August 23, 2011Assignee: L'Oreal S.A.Inventor: Sandrine Chodorowski-Kimmes
-
Patent number: 7989502Abstract: Modafinil is selectively delivered to the brain, minimizing delivery to the blood, of a person in need thereof by administering to the person a therapeutically-effective dosage of modafinil, wherein the dosage is less than 1 mg, formulated in a lipid microemulsion (LME) and selectively delivered to the upper third of the nasal cavity. The method may be implemented with an intranasal pharmaceutical delivery device loaded with a modafinil composition and adapted to deliver the dosage to the upper third of the nasal cavity.Type: GrantFiled: February 6, 2009Date of Patent: August 2, 2011Assignees: SRI International, HealthPartners Research FoundationInventors: Mary Ann Katherine Greco, William Howard Frey, II, Jacqueline DeRose, Rachel Beth Matthews, Leah Ranae Bresin Hanson
-
Patent number: 7973084Abstract: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, it can be effectively used in delivering various biologically active molecules, such as doxorubicin and paclitaxel to target cells.Type: GrantFiled: August 24, 2007Date of Patent: July 5, 2011Assignee: Postech Academy-Industrial FoundationInventors: Sung-Kee Chung, Woo Sirl Lee, Kaustabh Kumar Maiti
-
Patent number: 7964654Abstract: Compounds represented by the following structural formulas can be used as photoacid generators: Such compounds are useful, for example, in fabricating arrays of polymers.Type: GrantFiled: September 14, 2010Date of Patent: June 21, 2011Assignee: Affymetrix, Inc.Inventors: Glenn H. McGall, Andrea Cuppoletti
-
Patent number: 7960438Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Generalized Anxiety Disorder.Type: GrantFiled: April 4, 2007Date of Patent: June 14, 2011Assignee: Les Laboratoires ServierInventors: Bruno Delalleau, Agnes Fabiano, Mark Millan, Elisabeth Mocaer
-
Patent number: 7959723Abstract: The invention is directed to the use of compositions (a) biocides, and (b) dialkylamides, for wood protection.Type: GrantFiled: August 29, 2008Date of Patent: June 14, 2011Assignee: Cognis IP Management GmbHInventors: Joaquin Bigorra Llosas, Rainer Höfer, Bernd Fabry, Jean-Pierre Molitor, Stéphanie Merlet, Ramon Valls
-
Patent number: 7943600Abstract: This invention provides methods and pharmaceutical compositions for treating a subject having a condition associated with an antibiotic resistant bacterial infection. The invention includes administering to a subject a therapeutically effective combination of an antibiotic and a toxic compound (e.g., a nucleic acid damaging agent, an alkylating agent, or a heavy metal containing compound).Type: GrantFiled: December 20, 2005Date of Patent: May 17, 2011Assignees: Massachusetts Institute of Technology, University of MassachusettsInventors: Doriana Froim, John M. Essigmann, Martin G. Marinus
-
Publication number: 20110065762Abstract: The present invention relates, in part, to methods of treatment, prevention, and inhibition of viral disorders. In one aspect, the present invention relates to inhibition of the M2 proton channel of influenza viruses (e.g. influenza A virus) and other similar viroporins (e.g., VP24 of Ebola and Marburg viruses; and NS3 protein of Bluetongue). The present invention further relates, inter alia, to compounds which have been shown to possess antiviral activity, in particular, inhibiting the M2 proton channel of influenza viruses.Type: ApplicationFiled: September 13, 2010Publication date: March 17, 2011Inventors: Jizhou Wang, Xiaodong Fan, Lidia Cristian
-
Publication number: 20110052656Abstract: A process has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. According to one embodiment of the invention, antimicrobial compound containing liposomes are added to water systems prone to biofouling and biofilm formation. The liposomes, being similar in composition to microbial membranes or cells, are readily incorporated into the existing biofilm. Once the antimicrobial compound containing liposomes become entrained with the biofilm matrix, the decomposition or programmed disintegration of the liposome proceeds. Thereafter, the biocidal aqueous core is released to react directly with the biofilm encased microorganisms.Type: ApplicationFiled: September 28, 2010Publication date: March 3, 2011Applicant: GENERAL ELECTRIC COMPANYInventors: Wilson Kurt Whitekettle, Gloria Jean Tafel, Qing Zhao, Linna Wang, Dorothy Reynolds, Paul Frail, Juan Jiang, David M. Polizzotti
-
Patent number: 7879913Abstract: A method for decreasing nicotine and other substance use in humans is disclosed. Iptakalim hydrochloride (IPT) is a novel nicotine acetylcholine receptor (nAChR) blocker. According to the disclosed method, IPT is used to block human ?4?2-nAChR function. Specifically, IPT exhibits a selective blockade of ?4 subunit-containing human nAChR subtypes. According to the disclosed method, IPT is thus used to block the major nicotine targets in the brain, the ?4?2-nAChRs natively expressed in midbrain (VTA) DA system, the brain reward center, and in turn to reduce the nicotine-induced reward signals, namely dopamine level increase in nucleus accumbens. Therefore, IPT is capable of servicing as a nAChR antagonist agent and thus is a novel treatment for decreasing nicotine dependence in humans.Type: GrantFiled: June 28, 2005Date of Patent: February 1, 2011Assignee: Catholic Healthcare WestInventor: Jie Wu
-
Publication number: 20110003012Abstract: A method for attenuating vasoconstriction in a patient with subarachnoid hemorrhage by administering to the patient a therapeutically effective amount of a compound which mediates an increase of bioactive nitric oxide in blood or tissue in the subarachnoid space to cause vasodilation in cerebral, carotid and basilar arteries after the administration of the compound, and wherein the administration of the compound does not reduce mean arterial blood pressure by more than 10%.Type: ApplicationFiled: September 8, 2008Publication date: January 6, 2011Applicant: Duke UniversityInventors: Jonathan S. Stamler, David S. Warner, James D. Reynolds, Huaxin Sheng
-
Patent number: 7863344Abstract: Compounds represented by the following structural formulas can be used as photoacid generators: Such compounds are useful, for example, in fabricating arrays of polymers.Type: GrantFiled: November 3, 2008Date of Patent: January 4, 2011Assignee: Affymetrix, Inc.Inventors: Glenn H. McGall, Andrea Cuppoletti
-
Patent number: 7846975Abstract: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering various biologically active molecules.Type: GrantFiled: June 29, 2005Date of Patent: December 7, 2010Assignees: Postech Foundation, Postech Academy-Industry FoundationInventors: Sung-Kee Chung, Kaustabh Kumar Maiti, Woo Sirl Lee, Ock-Youm Jeon, Seok-Ho Lee
-
Patent number: 7820594Abstract: This invention relates to agricultural compositions, particularly pesticidal compositions which find particular use as a fungicide or herbicide composition. The pesticidal composition can include one or more fatty acids and one or more organic acids different from the fatty acid. The organic acid can but need not exhibit any fungicidal activity; however, when combined with a fatty acid, the organic acid functions as a potent synergist for the fatty acid as a fungicide. Additionally, the pesticidal composition can include other components such as emulsifiers, adjuvants, surfactants and diluents. The pesticidal composition significantly reduces or prevents the fungal infection of cash crops including vegetables, fruits, berries, seeds, grains and at higher application rates, can also be used as a herbicide and/or harvest aid or desiccant for harvested crops such as potatoes. The addition of an emulsifier further enhances the herbicidal properties of the compositions.Type: GrantFiled: June 25, 2007Date of Patent: October 26, 2010Inventor: Robert D. Coleman
-
Publication number: 20100173998Abstract: A personal care composition is provided which includes from 0.1 to 30% of a dihydroxypropyltri(C1-C3 alkyl) ammonium salt by weight of the composition; from 0.0001 to 0.005% of a tri(C1-C3 alkyl)amine or protonated form thereof by weight of the ammonium salt; from 0.002 to 15% of an aluminum salt by weight of the composition; and a cosmetically acceptable carrier wherein the composition has a pH ranging from 5.5 to 6.9. Unpleasant amine odor from trialkyl amines which arise from the dihydroxypropyltri(C1-C3 alkyl) ammonium salts is suppressed by the aluminum salt and by careful control of pH conditions.Type: ApplicationFiled: January 5, 2009Publication date: July 8, 2010Applicant: CONOPCO, INC., D/B/A UNILEVERInventors: Lin Yang, Neil Patrick Randle, Stephen Roy Barrow, Miguel Ortiz
-
Patent number: 7749526Abstract: Compounds of formula (I) are described for deterring vermin, wherein R is unbranched or branched C1-C15 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; R1 and R2 are unbranched or branched C1-C12 alkyl, preferably C1-C6 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; and X and Y, independently of one another, are a straightchain or branched alkylene bridge with 1 to 20 carbon atoms, preferably an alkylene bridge with 1 to 3 carbon atoms, which is unsubstituted or substituted by halogen, cyano or nitro. Furthermore, an essentially non-therapeutical process for deterring vermin is described, which is based on the usage of these compounds, as well as verminrepellent compositions containing these compounds as the active ingredient, and finally the use of these compounds for producing vermin-deterring compositions and their usage in deterring vermin from animals, humans and objects. New compounds within the scope of formula (I) are also described.Type: GrantFiled: December 16, 2003Date of Patent: July 6, 2010Assignee: Novartis AGInventors: Thomas Goebel, Tania Cavaliero, Jacques Bouvier
-
Patent number: 7740692Abstract: A wood preservative composition resulting from admixing components comprising: at least one preservative metal; a quaternary ammonium compound; at least 2 amine compounds; a pH reducing agent, and water, wherein the pH of the composition is from about 7.1 to less than 8.5. Surprisingly, this combination of materials results in a stable solution that can contain a moldicide yet have a commercially acceptable shelf life.Type: GrantFiled: June 7, 2006Date of Patent: June 22, 2010Inventors: Robert W. Grady, William C. Hoffman, Stephen W. King
-
Patent number: 7741244Abstract: This invention relates to agricultural compositions that find particular use as a fungicide composition. The fungicide composition can include one or more fatty acids and one or more organic acids different from the fatty acid. The organic acid can but need not exhibit any fungicidal activity; however, when combined with a fatty acid, the organic acid functions as a potent synergist for the fatty acid as a fungicide. Additionally, the fungicide composition can include other components such as emulsifiers, adjuvants, surfactants and diluents. The fungicide composition significantly reduces or prevents the fungal infection of cash crops including vegetables, fruits, berries, seeds, grains and at higher application rates, can also be used as a harvest aid or desiccant for harvested crops such as potatoes.Type: GrantFiled: January 9, 2003Date of Patent: June 22, 2010Inventor: Robert D. Coleman
-
Publication number: 20100113570Abstract: Methods for the use of uncompetitive NMDA receptor antagonist(s) in inhalational anesthesia are provided herein.Type: ApplicationFiled: April 23, 2009Publication date: May 6, 2010Applicants: The General Hospital Corporation, D/B/A MASSACHUSETTS GENERAL HISPITALInventors: Zhongcong Xie, Rudolph E. Tanzi
-
Patent number: 7700615Abstract: Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.Type: GrantFiled: February 1, 2006Date of Patent: April 20, 2010Assignee: Avolix Pharmaceuticals, Inc.Inventors: David L. Edwards, Michael E. Berens, Christian Beaudry
-
Publication number: 20100093857Abstract: Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.Type: ApplicationFiled: December 10, 2007Publication date: April 15, 2010Applicant: Genzyme CorporationInventors: Pradeep K. Dhal, Stephen Randall Holmes-Farley, Chad C. Huval
-
Publication number: 20100075894Abstract: Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide and glycerol. The present invention provides methods of treating a subject suffering from obesity, hyperglycemia, type 2 diabetes, or insulin resistance using ER stress reducers such as PBA, TUDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in ER stressed cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating obesity-associated diseases.Type: ApplicationFiled: August 13, 2009Publication date: March 25, 2010Applicant: HARVARD UNIVERSITYInventors: Gökhan S. Hotamisligil, Umut Özcan
-
Patent number: 7662222Abstract: This invention relates to the use of a combination of selected substances in paint to prevent the settlement and growth of different biofouling organisms with a reduced negative effect on the ecosystems compared to present methods.Type: GrantFiled: June 23, 2009Date of Patent: February 16, 2010Assignee: I-Tech ABInventors: Magnus Nydén, Camilla Fant
-
Patent number: 7658939Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.Type: GrantFiled: November 4, 2003Date of Patent: February 9, 2010Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
-
Publication number: 20090305886Abstract: Pesticidal mixtures comprising, as active components, 1) a malonodinitrile compound selected from compounds I-1 to I-8 CF2HCF2CF2CF2CH2C(CN)2CH2CH2CF3 (compound I-1; name: 2-(2,2,3,3,4,4,5,5-octofluoro-pentyl)-2-(3,3,3-trifluoro-propyl)-malononitrile); CF3(CH2)2C(CN)2CH2(CF2)5CF2H (compound I-2; name: 2-(2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-heptyl)-2-(3,3,3-trifluoro-propyl)-malononitrile); CF3(CH2)2C(CN)2(CH2)2C(CF3)2F (compound I-3; name: 2-(3,4,4,4-tetrafluoro-3-trifluoromethyl-butyl)-2-(3,3,3-trifluoro-propyl)-malononitrile); CF3(CH2)2C(CN)2(CH2)2(CF2)3CF3 (compound I-4; name: 2-(3,3,4,4,5,5,6,6,6-nonafluoro-hexyl)-2-(3,3,3-trifluoro-propyl)-malononitrile); CF2H(CF2)3CH2C(CN)2CH2(CF2)3CF2H (compound I-5; name: 2,2-bis-(2,2,3,3,4,4,5,5-octafluoro-pentyl)-malononitrile); CF3(CH2)2C(CN)2CH2(CF2)3CF3 (compound I-6; name: 2-(2,2,3,3,4,4,5,5,5-nonafluoro-pentyl)-2-(3,3,3-trifluoro-propyl)-malononitrile); CF3(CF2)2CH2C(CN)2CH2(CF2)3CF2H (compound I-7; name: 2-(2,2,3,3,4,4,4-heptafluoro-butyl)-2-(2,2,3,3,4,4,5,5-Type: ApplicationFiled: April 18, 2007Publication date: December 10, 2009Applicant: BASF SEInventors: Jürgen Langewald, Henry Van Tuyl Cotter, Deborah L. Culbertson, Hassan Oloumi-Sadeghi
-
Patent number: 7619007Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.Type: GrantFiled: November 22, 2005Date of Patent: November 17, 2009Assignee: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
-
Publication number: 20090258889Abstract: The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.Type: ApplicationFiled: April 3, 2009Publication date: October 15, 2009Applicant: Whitmire Micro-Gen Research Laboratories, Inc.Inventor: Steven R. Sims
-
Patent number: 7572798Abstract: The present invention relates to a series of new chemical agents that demonstrate anti-tumor activity. More particularly, the present invention relates to molecules, referred to as “combi-molecules”, that combine two major mechanisms of anti-tumor action. A combi-molecule is capable of degrading to a ligand involved in cell signaling pathways and to an agent capable of damaging DNA. More specifically, the present invention relates to molecules capable of blocking epidermal growth factor receptor (EGFR) mediated signal transduction and capable of damaging DNA. The present invention also relates to a general method of synthesis of these combi-molecules.Type: GrantFiled: February 26, 2002Date of Patent: August 11, 2009Assignee: McGill UniversityInventors: Bertrand J. Jean-Claude, Fabienne Dudouit, Stephanie Matheson